Ascrinvacumab

Drug Profile

Ascrinvacumab

Alternative Names: PF-03446962; PF-3-446-962

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Duke University Medical Center; Fondazione IRCCS Istituto Nazionale dei Tumori; Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ACVRL1-protein-antagonists; Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Liver cancer; Solid tumours; Urogenital cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 06 Nov 2014 Discontinued - Phase-I for Colorectal cancer (Combination therapy, Metastatic disease) in USA (IV)
  • 06 Nov 2014 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA, Italy & South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top